Created On: 2020-07-15
Record Count: 6
- cell therapy
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 203320
For the Exclusive Non-DC Products License, Licensor grants an exclusive license, even as to Licensor, in the Territory under Licensor Patent Rights and Program Patent Rights, Licensorâ€™s interest in Joint Program Patent Rights, Licensor Know-How, and Licensorâ€™s interest in Program Know-How to make, have made, use, offer to sell, sell and/or import Non-DC Product(s) (including use for research and development of such Non-DC Product(s)) for any and all uses in the Field.
For Non-Exclusive License to Conduct Assays, Licensor grants a non-exclusive license in the Territory under Licensor Patent Rights, Licensor Know-How, Licensor Program Patent Rights, Licensorâ€™s interest in Joint Program Patent Rights and Licensorâ€™s interest in Program Know-How, to the extent necessary to perform assays solely to measure immunological responses to Telomerase in the research, development, and commercialization of Non-DC Products under this Agreement, including monitoring of treatment in clinical trials and in support of commercial use of such Non-DC Products.
Licensee will have the right to grant sublicenses of these rights granted.
For the Research License. Licensor grants a non-exclusive license in the Territory under the Licensor Patent Rights and Know-How, Licensor Program Patent Rights and Licensorâ€™s interest in Joint Program Patent Rights and Licensorâ€™s interest in Program Know-How, and Materials, solely for the purpose of conducting research in those aspects of the Research Program pertaining to DC Products and DC/Adeno/DNA Therapies.
For the Option for Commercial License to DC Products: Licensor grants an exclusive option to enter into an exclusive arrangement, or non-exclusive arrangement if mutually agreed by the Parties, subject to any pre-existing obligations of Licensor to Third Parties, to develop and commercialize DC Products, DC/Non-DC Therapies and DC/Adeno/DNA Therapies, and obtain an exclusive license, or non-exclusive license if mutually agreed by the Parties, subject to any pre-existing obligations of Licensor to Third Parties, under the Licensor Patent Rights, Licensor Know-How, and Licensorâ€™s interest in Program Patent Rights and Program Know-How, in the Field, the DC Option. Licenseeâ€™s right to exercise the DC Option shall expire two (2) years after the Effective Date, unless otherwise agreed by the Parties. Licensee shall be entitled to exercise the DC Option by providing written notice to Licensor at any time prior to expiration of the DC Option.
Telomerase, also called terminal transferase, is a ribonucleoprotein that adds a species-dependent telomere repeat sequence to the 3' end of telomeres.
DC Product shall mean a Product that comprises a Dendritic Cell. A Dendritic Cell or DC shall mean a mammalian cell that, as part of an ex vivo or in vitro preparation, can be used to present an antigen to the immune system. For the avoidance of doubt, Dendritic Cells shall include, but not be limited to, the type of cells commonly referred to scientifically as dendritic cells.
Non-DC Product shall mean any Product that is not a DC Product, DC/Non-DC Therapy or a DC/Adeno/DNA Therapy, regardless of whether such Product employs any delivery enhancement technology (e.g. with or without electroporation). Non-DC Products shall include, but not be limited to, Adeno/DNA Products.
Licensee has expertise and access to intellectual property rights related to various vaccine platform technologies, including adenovirus and DNA-based vaccines.
Collaboration and license agreement is to develop a cancer vaccine targeting telomerase utilizing Licensor's expertise in vaccine technologies.
IPSCIO Record ID: 263905
This agreement includes non-exclusive grants back from Licensee to Licensor.
IPSCIO Record ID: 4396
Genes for Human Telomerase Reverse Transcriptase and Telomerase Variants
Nucleic Acids Encoding Human Telomerase Reverse Transcriptase and Related Homologs
Nucleic Acid Compositions for Eliciting an Immune Response Against Telomerase Reverse Transcriptase
Human Telomerase Reverse Transcriptase Polypeptides
Field of Use means use of telomerase as an antigen in an immunotherapeutic product for use in humans wherein the telomerase antigen is delivered using (i) patient monocyte-derived dendritic cells, or other patient blood or bone marrow-derived antigen presenting cells, (ii) human embryonic stem cell derived dendritic cells or other antigen presenting cells, or (iii) induced pluripotent stem cell derived dendritic cells or other antigen presenting cells.
IPSCIO Record ID: 286034
Licensor grants to the German Licensee an exclusive, royalty-bearing license under Licensor Technology to develop, make, have made, use, sell, and have sold Products throughout the Territory with the right to grant sublicenses, provided, however, that Licensor expressly retains the right to use such Licensor Technology outside the Field.
Bundled Product shall mean a Product that includes one or more other stand-alone Licensee products and is sold for a single price, regardless of whether the Product and other stand-alone products are packaged together or separately.
Cell Enrichment/Identification Product shall mean a Product designed for the enrichment and/or identification of cells from biological specimens, that includes an antibody and/or a probe for telomerase or telomere length within a mixture of two or more antibodies and/or probes, all of which enable the enrichment and/or identification of cells.
Licensor Patent shall mean a Patent, including Licensors undivided interest in any Joint Patent, which covers a method, apparatus, compound, chemical, material, or article of manufacture specific to telomerase and/or telomere length.
IPSCIO Record ID: 286090
Licensor grants to the Licensee of Japan a non-exclusive license under the Licensor Technology that is the subject of the Research Program solely to conduct the Research Program activities assigned to Licensee under the Research Plan.
Licensee shall have the exclusive right to utilize the Collaboration Technology to develop Collaboration Products for use and sale in the Licensee Territory and to commercialize the Collaboration Products in the Licensee Territory.
The developed intellectual property will aid in discovering new immunotherapy targets, and/or developing new dendritic cell-based immunotherapy products.
Dendritic cells (DCs) are antigen-presenting cells (also known as accessory cells) of the mammalian immune system. Their main function is to process antigen material and present it on the cell surface to the T cells of the immune system. They act as messengers between the innate and the adaptive immune systems.
IPSCIO Record ID: 237216
Licensor shall offer to Licensee, on a priority basis with respect to any Third Party, all Products that Licensor plans to develop as Project Manager.
Licensor grants preferential terms to Licensee for two (2) rights for a Development Option, the Preferential Options, among the twenty (20) held by Licensee.
Licensor grants an irrevocable option, the Exclusive License Option, to obtain, based on the Final Development Results, an exclusive license, including vis-a-vis Licensor and its Affiliates, for its rights to the Industrial Property of the Product in order to sell the Final Product, to cause it to be sold, to exploit it, to cause it be exploited in the Territory in the therapeutic indication covered by the corresponding Marketing Authorization.
The Product shall be marketed by Licensee, its Affiliates or its licensees, under a trade name chosen by joint agreement between the Parties and registered in the name and on behalf of Licensor, hereinafter the Trade Name.
Licensor shall submit to Licensee as soon as possible following the execution date of this Memorandum of Agreement, all its on-going Development Programs outstanding.
Licensor shall transmit to Licensee, all information necessary to enable Licensee to evaluate its interest and possibly exercise a right for a Development Option to such On-going Programs.
Licensor shall provide Licensee, through the Research Committee, and as soon as possible after obtaining each of them, with the in vitro proof of concept for any Product under development at IDM, and the in vivo safety data for such Product in the first six (6) treated patients.
Licensee shall have an Exclusive License Option for each Development Program carried out to its term in application of this Memorandum of Agreement, or a maximum possible credit equal to twenty (20) Exclusive License Option rights.
Licensor shall supply the Product to Licensee in the form of the Final Product.